Leonidas E Bantis
Overview
Explore the profile of Leonidas E Bantis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
807
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bantis L, Young K, Tsimikas J, Mosier B, Gajewski B, Yeatts S, et al.
Res Methods Med Health Sci
. 2023 Apr;
4(1):34-48.
PMID: 37009524
Studies that investigate the performance of prognostic and predictive biomarkers are commonplace in medicine. Evaluating the performance of biomarkers is challenging in traumatic brain injury (TBI) and other conditions when...
12.
Johnson B, Pham T, Young K, Bantis L, Sun W, Kasi A
Kans J Med
. 2022 Aug;
15:273-277.
PMID: 36042840
Introduction: Colon cancer impacts the lives of Kansans and those across the United States. Epidermal growth factor receptor (EGFR) inhibitors, such as panitumumab and cetuximab, have gained popularity as first-line...
13.
Medcalf M, Bantis L, Shi P, Bhadbhade P, Gundry R, Mikuls T, et al.
Semin Arthritis Rheum
. 2022 Jul;
56:152056.
PMID: 35785666
Objective: Methotrexate (MTX) remains the first-choice disease-modifying therapy in rheumatoid arthritis (RA). However, clinical response is variable, and no reliable predictive biomarkers of efficacy currently exist. In this study, plasma...
14.
Shi P, Bantis L
Biom J
. 2022 May;
64(6):1023-1039.
PMID: 35561036
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. Finding new biomarkers for its early detection is of high clinical importance. As with many other diseases, cancer...
15.
Bantis L, Tsimikas J
Stat Med
. 2022 May;
41(18):3527-3546.
PMID: 35543227
Pancreatic ductal adenocarcinoma (PDAC) is the most deadly cancer and currently there is strong clinical interest in novel biomarkers that contribute to its early detection. Assessing appropriately the accuracy of...
16.
Capello M, Fahrmann J, Rios Perez M, Vykoukal J, Irajizad E, Tripathi S, et al.
JCO Precis Oncol
. 2022 Jan;
4:426-436.
PMID: 35050739
Purpose: The combination chemotherapy of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has provided clinically meaningful improvement for pancreatic ductal adenocarcinoma (PDAC). We previously uncovered a role for the serine hydrolase...
17.
Eller O, Foright R, Brake A, Winter M, Bantis L, Morris E, et al.
Neuroscience
. 2021 Jun;
468:53-67.
PMID: 34107347
Inflammation plays a key role in the progression and maintenance of chronic pain, which impacts the lives of millions of Americans. Despite growing evidence that chronic pain can be improved...
18.
Mosier B, Bantis L
Stat Med
. 2021 Jun;
40(20):4522-4539.
PMID: 34080733
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive type of cancer with a 5-year survival rate of less than 5%. As in many other diseases, its diagnosis might involve progressive stages....
19.
Swint-Kruse L, Martin T, Page B, Wu T, Gerhart P, Dougherty L, et al.
Protein Sci
. 2021 Jun;
30(9):1833-1853.
PMID: 34076313
When amino acids vary during evolution, the outcome can be functionally neutral or biologically-important. We previously found that substituting a subset of nonconserved positions, "rheostat" positions, can have surprising effects...
20.
Bantis L, Nakas C, Reiser B
Biom J
. 2021 Apr;
63(6):1241-1253.
PMID: 33852754
Currently, there is global interest in deriving new promising cancer biomarkers that could complement or substitute the conventional ones. Clinical decisions can often be based on the cutoff that corresponds...